U.S. Department of Health and Human Services
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection
The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.
Brief Version (N/A)
Appendix B: Acronyms
General Terms
Last Updated: May 22, 2018; Last Reviewed: May 22, 2018
| Acronym | Term |
|---|---|
| °C | degrees Celsius |
| °F | degrees Fahrenheit |
| AE | adverse effect |
| ALP | alkaline phosphatase |
| ALT | alanine aminotransferase |
| ANC | absolute neutrophil count |
| APHL | Association of Public Health Laboratories |
| ART | antiretroviral therapy |
| ARV | antiretroviral |
| AST | aspartate aminotransferase |
| AUC | area under the curve |
| AUC0-12h | area under the curve at 12 hours post-dose |
| AUC24h | area under the curve at 24 hours post-dose |
| AV | atrioventricular |
| BCRP | breast cancer resistance protein |
| BID | twice daily |
| BMD | bone mineral density |
| BMI | body mass index |
| BSA | body surface area |
| C0h | pre-dose concentration |
| C12 or C12h | mid-dose concentration |
| CBC | complete blood count |
| CD4 | CD4 T lymphocyte |
| CDC | Centers for Disease Control and Prevention |
| CI | confidence interval |
| CK | creatine kinase |
| Cmax | maximum plasma concentration |
| Cmin | minimum plasma concentration |
| CMV | cytomegalovirus |
| CNS | central nervous system |
| CrCl | creatinine clearance |
| CT | continuous therapy |
| CV | coefficients of variation |
| CVD | cardiovascular disease |
| CYP | cytochrome P |
| dL | deciliter |
| DM | diabetes mellitus |
| DMPA | depot medroxyprogesterone acetate |
| DNA | deoxyribonucleic acid |
| DOT | directly observed therapy |
| DRESS | drug reaction (or rash) with eosinophilia and systemic symptoms |
| DSMB | Data Safety Monitoring Board |
| DXA | dual energy x-ray absorptiometry |
| EBV | Epstein-Barr virus |
| EC | enteric-coated |
| ECG or EKG | electrocardiogram |
| EEG | electroencephalogram |
| eGFR | estimated glomerular filtration rate |
| EM | erythema multiforme or extensive metabolizers |
| EMA | European Medicines Agency |
| FDA | Food and Drug Administration |
| FDC | fixed-dose combination |
| fL | femtoliter |
| fmol | femtomole |
| FLP | fasting lipid profile |
| FPG | fasting plasma glucose |
| G6PD | glucose-6-phosphate dehydrogenase |
| GFR | glomerular filtration rate |
| GI | gastrointestinal |
| GM | geometric mean |
| HAV | hepatitis A virus |
| HBV | hepatitis B virus |
| HCV | hepatitis C virus |
| HDL-C | high-density lipoprotein cholesterol |
| Hgb | hemoglobin |
| HgbA1c | glycosylated hemoglobin |
| HHS | Department of Health and Human Services |
| HIV RNA or HIV-1 RNA | viral load |
| HLA | human leukocyte antigen |
| HPV | human papilloma virus |
| HRSA | Health Resources and Services Administration |
| HSR | hypersensitivity reaction |
| HSV | herpes simplex virus |
| IAS-USA | International Antiviral Society-USA |
| ICH | intracranial hemorrhage |
| INH | isoniazid |
| INSTI | integrase strand transfer inhibitor |
| IQ | inhibitory quotient |
| IQR | interquartile range |
| IRIS | immune reconstitution inflammatory syndrome |
| IU | international units |
| IV | intravenous |
| IVIG | intravenous immune globulin |
| kg | kilogram |
| L | liter |
| LDL | low-density lipoprotein |
| LDL-C | low-density lipoprotein cholesterol |
| LFT | liver function test |
| LLD | lower level of detection |
| LLQ | lower limits of quantitation |
| LS | lipodystrophy syndrome |
| mcg or μg | microgram |
| MCV | mean cell volume |
| mg | milligram |
| min | minute |
| mL | milliliter |
| mm | millimeter |
| NASBA | nucleic acid sequence-based amplification |
| NAT | nucleic acid test |
| ng | nanogram |
| NHLBI | National Heart, Lung, and Blood Institute |
| NIH | National Institutes of Health |
| NNRTI | non-nucleoside reverse transcriptase inhibitor |
| NRTI | nucleoside reverse transcriptase inhibitor |
| OARAC | Office of AIDS Research Advisory Council |
| OBT | optimized background therapy |
| OGTT | oral glucose tolerance test |
| OI | opportunistic infection |
| oz | ounce |
| PBMC | peripheral blood mononuclear cell |
| PCP | Pneumocystis jirovecii pneumonia |
| PCR | polymerase chain reaction |
| PEP | post-exposure prophylaxis |
| PG | plasma glucose |
| P-gp | P-glycoprotein |
| PI | protease inhibitor |
| PK | pharmacokinetic |
| PPI | proton pump inhibitor |
| PUFA | polyunsaturated fatty acid |
| py | patient years |
| QTc | corrected QT |
| RBV | ribavirin |
| RNA | ribonucleic acid |
| RPG | random plasma glucose |
| RT-PCR | reverse transcription polymerase chain reaction |
| SCT | short-cycle therapy |
| SD | standard deviation |
| SDD | study drug discontinuation |
| SJS | Stevens-Johnson syndrome |
| SM | slow metabolizers |
| SMR | sexual maturity rating |
| SQ | subcutaneous |
| STI | sexually transmitted infection |
| T½ | half-life |
| TB | tuberculosis |
| TC | total cholesterol |
| TDM | therapeutic drug monitoring |
| TEN | toxic epidermal necrolysis |
| TFV | tenofovir |
| TFV-DP | tenofovir diphosphate |
| TG | triglyceride |
| THAM | tris (hydroxymethyl) aminomethane |
| Tmax | time to reach maximum concentration |
| TMP-SMX | trimethoprim sulfamethoxazole |
| UGT | uridine diphosphate glucuronosyltransferase |
| ULN | upper limit of normal |
| VLS | viral load suppression |
| WHO | World Health Organization |
Download Guidelines
- Section Only PDF (894 KB)
- Full Guideline PDF ()
- Recommendations Only PDF (205 KB)
- Tables Only PDF (697 KB)
- Drug Tables Only PDF (1.5 MB)
Email Updates
